<?xml version="1.0" encoding="UTF-8"?>
<ref id="B30-molecules-25-00183">
 <label>30.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Khanna</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Dalby</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Tan</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Arnold</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Stern</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Frazer</surname>
    <given-names>N.</given-names>
   </name>
  </person-group>
  <article-title>Phase I/II clinical safety studies of terameprocol vaginal ointment</article-title>
  <source>Gynecol. Oncol.</source>
  <year>2007</year>
  <volume>107</volume>
  <fpage>554</fpage>
  <lpage>562</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ygyno.2007.08.074</pub-id>
  <pub-id pub-id-type="pmid">17905420</pub-id>
 </element-citation>
</ref>
